The future of human health will be defined by technologies that accelerate the world's access to more effective medicines.
Human cells are a cornerstone of fundamental disease research, drug discovery, and clinical translation. Yet, despite decades of research into iPSCs, emerging cures for some of the world’s most pervasive diseases have been bottlenecked by a lack of access to standardised, easy to use and readily accessible human cells.
We built ioCells to solve this challenge.
Developed on our platform, and powered by opti-ox technology, ioCells are human cells deterministically programmed from iPSCs consistently, at scale. With ioCells, scientists no longer need to battle with variance, unreliability, physiological irrelevance and long experimental timelines. Instead, scientists can finally focus on the next great advances in human health.
ioCells are for research use only.
ioWild Type Cells
ioWild Type Cells are defined, easy-to-use, functional iPSC-derived human cells from a healthy donor background that are ready for fundamental research and drug discovery experimentation within days.
ioDisease Model Cells
ioDisease Model Cells are ioWild Type Cells engineered to contain disease-relevant mutations. ioDisease Model Cells and ioWild Type Cells form an isogenic pair allowing scientists to make true comparisons.
CRISPR-Ready ioCells
CRISPR-Ready ioCells are human iPSC-derived cells constitutively expressing Cas9 nuclease for rapid gene knockout generation.
ioTracker Cells
ioTracker Cells are human iPSC-derived cells constitutively expressing a fluorescent protein for easy visualisation, tracking, and isolation of human cells in live-cell imaging assays.
Consistent
Our platform ensures consistency between every batch of cells, overcoming the challenge of data reproducibility.
Cost-effective
ioCells generate quality data at industry leading seeding densities. You can do more with every vial as every well saves you money.
Defined
Every ioCell has its identity characterised by ICC, RT-qPCR and RNA-Seq at minimum.
Easy-to-use
ioCells are delivered cryopreserved and require a simple protocol using an open-source medium to get started.
Quick
Deterministically programmed cells mature rapidly, meaning cells are ready for experimentation and data gathering within days post-revival.
Scalable
With opti-ox technology we can make billions of consistently programmed cells, surpassing the demands of industrial workflows.
Dr Marijn Vlaming
Head of Biology - Beerse & Leiden | Charles River
Dr Mariangela Iovino
Senior Group Leader | Biology Discovery | Charles River
Rodney A. Bowling Jr, PhD
Co-Founder & Chief Scientific Officer | Everlum Bio
Every ioCell is powered by opti-ox.
Using opti-ox, populations of stem cells are precisely and consistently programmed into a chosen cell identity. Each vial of ioCells contains a defined and highly characterised population of iPSC-derived human cells that are ready for quality data production in a matter of days. Their high lot-to-lot consistency provides a reliable cell model that enables scientists to conduct repeatable and scalable experiments in drug discovery and disease research.
Lachize, et al
Courtesy of Charles River Laboratories
2020
Oosterveen, et al
91̽
2022
Raman, et al
91̽
2022
Dr Mitchell Han
Bi/ond
2023
Vaquero, et al
91̽
2023
Smith, et al.
91̽
2024
Foulser, et al
91̽
2024
Schmidt, et al
91̽
2024
Bernard, et al
91̽
2024
Schmidt et al.
91̽
2024
Veteleanu et al.
91̽
2025
Bsibsi et al.
Courtesy of Charles River Laboratories
2024
Oosterveen et al.
91̽
2025
Bsibsi et al.
Courtesy of Charles River Laboratories
2024
Iovino et al.
Courtesy of Charles River Laboratories
2023
Newman et al.
91̽
2024
Herrera-Vaquero et al.
91̽
2024
Bsibsi et al.
Courtesy of Charles River Laboratories
2024
Brown et al.
91̽
2024
Grabner et al.
91̽
2025
Smith et al.
91̽
2024
Oosterveen et al.
91̽
2024
Monteith et al.
91̽
2024
Krainz et al.
91̽
2024
Veteleanu et al.
91̽
2025
Veteleanu et al.
91̽
2025
Yates et al.
91̽
2025
Foulser et al.
91̽
2025
Veteleanu et al.
91̽
2025
Tatar Ozkan et al.
91̽
2025
Newman et al.
91̽
2026
Schmidt et al.
91̽
2026
Hill et al.
91̽
2026
Harris-Brown et al.
91̽
2026
Dr Alex Davenport | Senior Scientist | 91̽
Talk at ELRIG Cell & Gene Therapy
2021
Kam Dhaliwal | SVP Strategic Alliances | 91̽
Talk at ELRIG CRISPR in Drug Discovery
Kam Dhaliwal | SVP Strategic Alliances | 91̽
Dr Thomas Moreau | Head of Research | 91̽
Talk at ELRIG Drug Discovery Digital
91̽ (chair) | AstraZeneca | PhoreMost Ltd | Aelian Biotechnology GmbH | Charles River
Panel discussion at ELRIG Drug Discovery Digital
Kings College London & 91̽
Panel discussion at Oxford Global Discovery UK
Innovation showcase talk at ISSCR
Marius Wernig MD, PhD | Stanford
Mark Kotter, MD, PhD | 91̽
Dr Emmanouil Metzakopian | Visiting researcher | University of Cambridge
Human Cell Forum 2025
Session 1 Track 1 | Modelling neurodegeneration in vitro with human iPSC-derived cells
Dr Irantzu Perez Ruiz | Study Director | Scantox Neuro
Human Cell Forum 2025
Session 1 Track 1 | Modelling neurodegeneration in vitro with human iPSC-derived cells
Dr Elizabeth Di Lullo | Associate Scientific Director | BrainEver
Human Cell Forum 2025
Session 1 Track 1 | Modelling neurodegeneration in vitro with human iPSC-derived cells
Dr Ryan Jones | Research Associate | Cardiff University
Human Cell Forum 2025
Session 1 Track 2 | From cells to systems: Building human iPSC-derived models of pain, neuromuscular junctions, and glial dynamics
Jeremy Krohn | PhD Candidate | DZNE / Charité University of Medicine
Human Cell Forum 2025
Session 1 Track 2 | From cells to systems: Building human iPSC-derived models of pain, neuromuscular junctions, and glial dynamics
Dr Grace Cooper | Senior Scientist | 91̽
Human Cell Forum 2025
Session 1 Track 2 | From cells to systems: Building human iPSC-derived models of pain, neuromuscular junctions, and glial dynamics
Luke Foulser | Field Applications Scientist | 91̽
Human Cell Forum 2025
Session 2 | 91̽ insider: Tools, tips, and what’s coming next
Euan Yates | Scientist | 91̽
Human Cell Forum 2025
Session 2 | 91̽ insider: Tools, tips, and what’s coming next
Dr Gianmarco Mastrogiovanni | Principal Scientist - Cell Type Development | 91̽
Human Cell Forum 2025
Session 2 | 91̽ insider: Tools, tips, and what’s coming next
Sejla Salic-Hainzl | Vice President of R&D | 91̽ discovery
Human Cell Forum 2025
Session 2 | 91̽ insider: Tools, tips, and what’s coming next
Dr Martina Esposito Soccoio | Senior Research Associate | AviadoBio
Human Cell Forum 2025
Session 3 | Making complex human biology compatible with modern drug discovery workflows
Dr Sara Martin | Scientist | Axxam
Human Cell Forum 2025
Session 3 | Making complex human biology compatible with modern drug discovery workflows
Dr Ben Bar-Sadeh | Senior Scientist | Anima Biotech
Human Cell Forum 2025
Session 3 | Making complex human biology compatible with modern drug discovery workflows
Dr Marijn Vlaming | Head of Biology, et al.
Charles River & 91̽
Dr Marijn Vlaming | Head of Biology
Charles River
Dr Shushant Jain | Group Leader In Vitro Biology | Charles River
Interview at SLAS
Dr Will Bernard | Director of Cell Type Development | 91̽
91̽
V2
91̽
2023
Luke Foulser | Scientist | 91̽
Dr Daniel Ortmann | Head of Discovery | 91̽
Dr Anne-Claire Guénantin | Senior Scientist | 91̽
Dr Will Bernard | Senior Scientist | 91̽
Dr Tony Oosterveen | Senior Scientist | 91̽
Dr Kaiser Karim | Senior Scientist | 91̽
Dr Thomas Moreau | Head of Research | 91̽
Dr Thomas Moreau | Head of Research | 91̽
Dr Eric Hill | Reader in Cellular and Molecular Neurobiology | Loughborough University
Dr Mariangela Iovino | Senior Group Leader | Charles River Laboratories
Prof Hagan Bayley | University of Oxford
Dr Mark Kotter | Founder and CEO | 91̽
Dr Luke Flatt | Senior Scientist | Charles River Laboratories
Dr Will Bernard | Senior Scientist | 91̽
Dr Deepak Srivastava | King’s College London
Dr Mariangela Iovino | Group Leader | Charles River
Dr Tony Oosterveen | Senior Scientist | 91̽
Dr Emma V Jones | Senior Scientist | Medicines Discovery Catapult
Dr Tony Oosterveen | Senior Scientist | 91̽
Dr Matthias Pawlowski | Head, Dementia-Sensitive Hospital | University of Münster
Dr Malathi Raman | Senior Product Manager | 91̽
Rodney A. Bowling Jr., Ph.D. | Chief Scientific Officer | Everlum Bio
Malathi Raman Ph.D. | Senior Product Manager | 91̽
Mark Kotter | CEO and founder | 91̽
Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology | Stanford University
Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | 91̽
Prof Roger Pedersen | Adjunct Professor and Senior Research Scientist at Stanford University
Dr Thomas Moreau | Director of Cell Biology Research | 91̽
Dr Marieke Aarts | Principal Scientist | Bi/ond
Amanda Turner | Senior Product Manager | 91̽
Emmanouil Metzakopian | Vice President, Research and Development | 91̽
Javier Conde-Vancells | Director Product Management | 91̽
Tom Brown | Senior Product Manager | 91̽
Marcos Herrera Vaquero, PhD | Senior Scientist | 91̽Dr Brian Gill, MD | Assistant Professor of Neurological Surgery| Columbia University Irving Medical Center
Dr Tony Oosterveen | Principal Scientist and CNS Lead, Neurobiology | 91̽
Professor Luke Gilbert | Associate Professor | University of California San Francisco
Sejla Salic-Hainzl | Vice President of Research and Development | 91̽
Stephen Ferguson, PhD | Investigator, Mechanistic Toxicology | Division of Translational Toxicology (DTT) | National Institute of Environmental Health Sciences
Tom Brown | Senior Product Manager | 91̽
Antonella Santuccione Chadha, MD | Founder and CEO | Women’s Brain Foundation
Melanie Einsiedler, PhD | Scientific Contributor | Women’s Brain Foundation
Rebecca Northeast, PhD | Senior Product Manager | 91̽
Sebastian Fiedler, PhD | Applications Marketing Manager | 91̽
Malika Bsibsi, PhD | Research Leader Neuroscience | Charles River Laboratories
Austin Passaro, PhD | Global Product Manager MEA | Axion Biosystems
Cicely Schramm, PhD | Head of Biology Imaging | Sartorius
Ben Bar-Sadeh, PhD | Senior Scientist | Anima Biotech
Tom Brown | Senior Product Manager | 91̽
Marius Wernig, Professor | Departments of Pathology and Chemical, and Systems Biology and Co-Director of the Institute for Stem Cell Biology and Regenerative Medicine | Stanford University
Samantha Morris, PhD | Principle Investigator | Brigham and Women’s Hospital and Harvard Medical School, Department of Systems Biology
Thomas Moreau, PhD | Vice President of Cell Programming Research | 91̽
Luke Foulser, MSc | Field Applications Scientist | 91̽
Austin Passaro, PhD | Global Product Manager MEA | Axion Biosystems
Jack Gowen, MSc | Scientist, QC and GMP, Analytical Development | 91̽
Charlotte Durham, BSc | Operational Quality Manager | 91̽
Thomas Moreau, PhD | VP Cell Programming Research | 91̽
Ann Byrne, MSc | Regional Sales Manager, APAC | 91̽
Gianmarco Mastrogiovanni, PhD | Principle Scientist - Cell Type Development | 91̽
Fuad Mosis, PhD | Technical Support Specialist | 91̽
Sarah Hussain | Scientist | 91̽
Tulin Tatar Ozkan, PhD | Senior Scientist II | 91̽